Abby Jacobson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abby Jacobson has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- April W. Armstrong
University of California, Los Angeles, USA
6 shared publications - Mark Lebwohl
Icahn School of Medicine at Mount Sinai
4 shared publications - Bruce Strober
Yale School of Medicine, New Haven, USA
3 shared publications - Earl L. Goehring
Bausch Health Companies Inc, Bridgewater, USA
3 shared publications - John Koo
Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, USA
3 shared publications - Nicole N. Rawnsley
Bausch Health Companies Inc, Bridgewater, USA
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71115
Next‐Generation Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System: Provider and Patient Perspectives
- 2 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71115
Open AccessNext‐Generation Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System: Provider and Patient Perspectives
- Open Access
- 10 February 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (3) , 169-179
Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐ablative Fractional Laser System Treatment in Patients With Skin of Color: A Review of Clinical Studies and Unmet Needs
Objectives: To review the efficacy and safety of the dual 1550‐nm erbium glass fiber and 1927‐nm thulium fiber non‐ablative fractional laser system in patients with skin of color (ie, Fitzpatrick skin types [FSTs] III–VI). Materials and Methods: Efficacy, safety, and histologic outcomes were reviewed from 15 clinical studies examining the use of the 1550‐nm or 1927‐nm wavelength treatment in individuals with skin of color. Results: Despite variability across study designs, consistent improvement was reported with the 1550‐nm wavelength for the treatment of scarring and melasma and the 1927‐nm wavelength for the treatment of melasma and photoaging. Postinflammatory hyperpigmentation (PIH) rates varied across studies. Studies directly comparing different settings reported reduced PIH rates with lower energy and/or density. Histologic studies confirmed dermal remodeling and reduced melanin after treatment. Conclusion: The 1550/1927‐nm dual‐laser system is safe and effective. Reducing pulse energy and density may confer fewer adverse effects in patients with skin of color. Additional studies are needed, particularly for patients with FST VI and the 1927‐nm wavelength treatment.
- 10 February 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (3) , 169-179
Open AccessDual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐ablative Fractional Laser System Treatment in Patients With Skin of Color: A Review of Clinical Studies and Unmet Needs
Objectives: To review the efficacy and safety of the dual 1550‐nm erbium glass fiber and 1927‐nm thulium fiber non‐ablative fractional laser system in patients with skin of color (ie, Fitzpatrick skin types [FSTs] III–VI). Materials and Methods: Efficacy, safety, and histologic outcomes were reviewed from 15 clinical studies examining the use of the 1550‐nm or 1927‐nm wavelength treatment in individuals with skin of color. Results: Despite variability across study designs, consistent improvement was reported with the 1550‐nm wavelength for the treatment of scarring and melasma and the 1927‐nm wavelength for the treatment of melasma and photoaging. Postinflammatory hyperpigmentation (PIH) rates varied across studies. Studies directly comparing different settings reported reduced PIH rates with lower energy and/or density. Histologic studies confirmed dermal remodeling and reduced melanin after treatment. Conclusion: The 1550/1927‐nm dual‐laser system is safe and effective. Reducing pulse energy and density may confer fewer adverse effects in patients with skin of color. Additional studies are needed, particularly for patients with FST VI and the 1927‐nm wavelength treatment.
- Open Access
- 12 November 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (11) , e70523
Safety and Tolerability of the 1440‐ and 1927‐nm Non‐Ablative Fractional Diode Laser System for Skin Resurfacing: A Review of Current Literature
Background: Energy‐based devices, such as lasers, provide effective treatments for skin resurfacing. Ablative fractional lasers have a higher risk of adverse events (AEs), like scarring and postinflammatory hyperpigmentation, particularly in patients with darker skin types, than non‐ablative fractional lasers. The 1440‐ and 1927‐nm non‐ablative fractional diode laser (NFDL) system is indicated for use in dermatological procedures requiring the coagulation of soft tissue and for general skin resurfacing procedures. Aim: To help inform clinical decision‐making about the dual 1440/1927‐nm NFDL system, particularly for treating patients with diverse skin types who require safe and effective resurfacing treatments. Methods: A PubMed search of literature was conducted to review safety and tolerability outcomes from clinical studies of 1440‐ and 1927‐nm NFDL treatments. Results: Expected skin reactions, including erythema, edema, and crusting, were mild to moderate and self‐limited for concurrent and individual use of the 1440‐ and 1927‐nm handpieces. Mild discomfort and heat sensation, which were also expected, indicated that treatment was well tolerated. Safety was also demonstrated in patients with skin of color, with no serious AEs. Levels of patient satisfaction were high. Conclusions: The dual 1440/1927‐nm NFDL system is a safe and well‐tolerated option for resurfacing of diverse skin types with minimal postprocedural downtime and reduced risk of AEs relative to ablative lasers.
- 12 November 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (11) , e70523
Open AccessSafety and Tolerability of the 1440‐ and 1927‐nm Non‐Ablative Fractional Diode Laser System for Skin Resurfacing: A Review of Current Literature
Background: Energy‐based devices, such as lasers, provide effective treatments for skin resurfacing. Ablative fractional lasers have a higher risk of adverse events (AEs), like scarring and postinflammatory hyperpigmentation, particularly in patients with darker skin types, than non‐ablative fractional lasers. The 1440‐ and 1927‐nm non‐ablative fractional diode laser (NFDL) system is indicated for use in dermatological procedures requiring the coagulation of soft tissue and for general skin resurfacing procedures. Aim: To help inform clinical decision‐making about the dual 1440/1927‐nm NFDL system, particularly for treating patients with diverse skin types who require safe and effective resurfacing treatments. Methods: A PubMed search of literature was conducted to review safety and tolerability outcomes from clinical studies of 1440‐ and 1927‐nm NFDL treatments. Results: Expected skin reactions, including erythema, edema, and crusting, were mild to moderate and self‐limited for concurrent and individual use of the 1440‐ and 1927‐nm handpieces. Mild discomfort and heat sensation, which were also expected, indicated that treatment was well tolerated. Safety was also demonstrated in patients with skin of color, with no serious AEs. Levels of patient satisfaction were high. Conclusions: The dual 1440/1927‐nm NFDL system is a safe and well‐tolerated option for resurfacing of diverse skin types with minimal postprocedural downtime and reduced risk of AEs relative to ablative lasers.
- 23 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5451-5467
IL-17C as a Driver of Inflammation in Psoriasis
In psoriatic lesions, interleukin (IL)-17C protein expression has been reported as high as 125 times that of IL-17A; as such, it is crucial to understand the role that IL-17C plays in psoriasis, inflammation, and treatment response. Overexpression or injection of IL-17C in mice results in increased epidermal thickening and inflammation, whereas psoriatic mice with IL-17C knockout have decreased disease severity compared with control littermates. In psoriasis, IL-17C likely acts as a critical inflammatory amplifier via a feed-forward mechanism, wherein IL-17-producing CD4+ helper T (TH17) cells and IL-17-producing CD8+ cytotoxic T (TC17) cells stimulate IL-17C expression in keratinocytes. Then, keratinocyte-derived IL-17C induces IL-17A expression in TH17 and TC17 cells. Additionally, keratinocyte-derived IL-17C propagates its own signaling in an autocrine manner. Furthermore, studies suggest that IL-17C acts as an early mediator of psoriasis. No approved therapies directly target IL-17C. Brodalumab is an IL-17 receptor (IL-17R) A antagonist that inhibits IL-17A, F, C, and E signaling and has a unique mechanism of action among biologic therapies for psoriasis. By way of IL-17RA blockade, brodalumab is the only approved therapy for psoriasis that inhibits IL-17C signaling. This unique mechanism of action is hypothesized to correlate with efficacy in patients with prior failures to anti–IL-17A therapies and relatively higher rates of early skin clearance compared with those of other biologic therapies. Clinical studies are needed to confirm these correlations. In summary, IL-17C is an inflammatory amplifier and early psoriatic mediator, and inhibition of IL-17C may be beneficial in psoriasis management.
- 23 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5451-5467
IL-17C as a Driver of Inflammation in Psoriasis
In psoriatic lesions, interleukin (IL)-17C protein expression has been reported as high as 125 times that of IL-17A; as such, it is crucial to understand the role that IL-17C plays in psoriasis, inflammation, and treatment response. Overexpression or injection of IL-17C in mice results in increased epidermal thickening and inflammation, whereas psoriatic mice with IL-17C knockout have decreased disease severity compared with control littermates. In psoriasis, IL-17C likely acts as a critical inflammatory amplifier via a feed-forward mechanism, wherein IL-17-producing CD4+ helper T (TH17) cells and IL-17-producing CD8+ cytotoxic T (TC17) cells stimulate IL-17C expression in keratinocytes. Then, keratinocyte-derived IL-17C induces IL-17A expression in TH17 and TC17 cells. Additionally, keratinocyte-derived IL-17C propagates its own signaling in an autocrine manner. Furthermore, studies suggest that IL-17C acts as an early mediator of psoriasis. No approved therapies directly target IL-17C. Brodalumab is an IL-17 receptor (IL-17R) A antagonist that inhibits IL-17A, F, C, and E signaling and has a unique mechanism of action among biologic therapies for psoriasis. By way of IL-17RA blockade, brodalumab is the only approved therapy for psoriasis that inhibits IL-17C signaling. This unique mechanism of action is hypothesized to correlate with efficacy in patients with prior failures to anti–IL-17A therapies and relatively higher rates of early skin clearance compared with those of other biologic therapies. Clinical studies are needed to confirm these correlations. In summary, IL-17C is an inflammatory amplifier and early psoriatic mediator, and inhibition of IL-17C may be beneficial in psoriasis management.
- Open Access
- 19 September 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (11) , 3253-3266
Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure
This narrative review evaluates the clinical evidence supporting brodalumab as a second-line therapy against moderate-to-severe plaque psoriasis in adults who have experienced prior systemic treatment failure. Despite advances in biologic therapy, treatment failure remains a substantial challenge, with patients often discontinuing initial biologic treatment owing to inadequate response. Here, we analyzed data from clinical trials, real-world studies, and observational research examining brodalumab’s efficacy in treatment-experienced populations. Unlike other biologics that target specific interleukin 17 (IL-17) cytokines, brodalumab blocks the IL-17 receptor A and prevents signaling from multiple IL-17 family members, potentially explaining its effectiveness in treatment-resistant cases. The evidence presented here demonstrates rapid Psoriasis Area and Severity Index response rates, as well as durable efficacy of brodalumab in patients after a failed treatment with previous biologic therapies. This narrative review synthesizes the current evidence base for brodalumab’s role specifically in the second-line setting, providing clinicians with a comprehensive assessment of its efficacy in treatment-resistant psoriasis. Graphical Abstract
- 19 September 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (11) , 3253-3266
Open AccessBrodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure
This narrative review evaluates the clinical evidence supporting brodalumab as a second-line therapy against moderate-to-severe plaque psoriasis in adults who have experienced prior systemic treatment failure. Despite advances in biologic therapy, treatment failure remains a substantial challenge, with patients often discontinuing initial biologic treatment owing to inadequate response. Here, we analyzed data from clinical trials, real-world studies, and observational research examining brodalumab’s efficacy in treatment-experienced populations. Unlike other biologics that target specific interleukin 17 (IL-17) cytokines, brodalumab blocks the IL-17 receptor A and prevents signaling from multiple IL-17 family members, potentially explaining its effectiveness in treatment-resistant cases. The evidence presented here demonstrates rapid Psoriasis Area and Severity Index response rates, as well as durable efficacy of brodalumab in patients after a failed treatment with previous biologic therapies. This narrative review synthesizes the current evidence base for brodalumab’s role specifically in the second-line setting, providing clinicians with a comprehensive assessment of its efficacy in treatment-resistant psoriasis. Graphical Abstract
- Open Access
- 29 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (10) , 3025-3035
Brodalumab: Seven-Year US Pharmacovigilance Report
Introduction Brodalumab, a human interleukin-17 receptor A antagonist, is approved for treating adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy and have experienced treatment failure or loss of response to other systemic treatments. Although brodalumab is distributed in the USA under a Risk Evaluation and Mitigation Strategy that includes a boxed warning regarding suicidal ideation and behavior, a direct causal relationship has not been established. This report examines pharmacovigilance data collected over 7 years of clinical usage to provide an assessment of the long-term safety characteristics of brodalumab. Methods This report evaluated adverse events (AEs) submitted to Ortho Dermatologics from US healthcare providers and patients during the period spanning August 15, 2017 to August 14, 2024. We calculated crude AE reporting rates per 100 patients using Medical Dictionary for Regulatory Activities (MedDRA) v27.0 Preferred Terms and standardized MedDRA queries. Treatment duration was determined by measuring the time between initial and latest prescription-dispensing authorization dates. Results The study encompassed 5449 US patients, representing approximately 7845 patient-years of exposure across the 7-year reporting period. There were no new adjudicated cases of major adverse cardiovascular events in year 7 (0.24/100 patients for the 7-year reporting period), and serious infection cases occurred at a rate of 2.17/100 patients. Among 64 reported malignancies in 55 patients, 4 were assessed as potentially treatment related. Throughout the 7-year period, no completed suicides were reported, and one suicide attempt occurred in year 3. Conclusion The 7-year pharmacovigilance dataset reinforces the safety profile of brodalumab previously established through clinical trials and earlier pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical Abstract
- 29 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (10) , 3025-3035
Open AccessBrodalumab: Seven-Year US Pharmacovigilance Report
Introduction Brodalumab, a human interleukin-17 receptor A antagonist, is approved for treating adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy and have experienced treatment failure or loss of response to other systemic treatments. Although brodalumab is distributed in the USA under a Risk Evaluation and Mitigation Strategy that includes a boxed warning regarding suicidal ideation and behavior, a direct causal relationship has not been established. This report examines pharmacovigilance data collected over 7 years of clinical usage to provide an assessment of the long-term safety characteristics of brodalumab. Methods This report evaluated adverse events (AEs) submitted to Ortho Dermatologics from US healthcare providers and patients during the period spanning August 15, 2017 to August 14, 2024. We calculated crude AE reporting rates per 100 patients using Medical Dictionary for Regulatory Activities (MedDRA) v27.0 Preferred Terms and standardized MedDRA queries. Treatment duration was determined by measuring the time between initial and latest prescription-dispensing authorization dates. Results The study encompassed 5449 US patients, representing approximately 7845 patient-years of exposure across the 7-year reporting period. There were no new adjudicated cases of major adverse cardiovascular events in year 7 (0.24/100 patients for the 7-year reporting period), and serious infection cases occurred at a rate of 2.17/100 patients. Among 64 reported malignancies in 55 patients, 4 were assessed as potentially treatment related. Throughout the 7-year period, no completed suicides were reported, and one suicide attempt occurred in year 3. Conclusion The 7-year pharmacovigilance dataset reinforces the safety profile of brodalumab previously established through clinical trials and earlier pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical Abstract
- 9 July 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (7) , 561-570
Current Trends and Future Directions of the Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System
Objectives: To synthesize current evidence and trends supporting the dual 1550‐nm erbium glass fiber and 1927‐nm thulium fiber non‐ablative fractional laser system's mechanism of action and proven efficacy and safety profile in addressing aging skin concerns.Methods: A review of current evidence and expert consensus was conducted to evaluate the 1550/1927‐nm dual laser system. The analysis focused on the 1550 and 1927‐nm lasers' specific mechanisms of action and their applications in treating various skin conditions.Results: The 1550‐nm laser effectively targets dyschromia, fine lines, and various types of scars, while the 1927‐nm laser specifically addresses actinic keratoses, dyschromia, and pigmented lesions. Expert consensus has established standardized protocols while emphasizing personalized treatment approaches on the basis of factors including treatment area and Fitzpatrick skin type.Conclusion: The 1550/1927‐nm dual laser system's ability to offer customizable settings positions it as a versatile tool in the growing field of esthetic medicine, particularly for addressing the multiple components of skin aging.
- 9 July 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (7) , 561-570
Current Trends and Future Directions of the Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System
Objectives: To synthesize current evidence and trends supporting the dual 1550‐nm erbium glass fiber and 1927‐nm thulium fiber non‐ablative fractional laser system's mechanism of action and proven efficacy and safety profile in addressing aging skin concerns.Methods: A review of current evidence and expert consensus was conducted to evaluate the 1550/1927‐nm dual laser system. The analysis focused on the 1550 and 1927‐nm lasers' specific mechanisms of action and their applications in treating various skin conditions.Results: The 1550‐nm laser effectively targets dyschromia, fine lines, and various types of scars, while the 1927‐nm laser specifically addresses actinic keratoses, dyschromia, and pigmented lesions. Expert consensus has established standardized protocols while emphasizing personalized treatment approaches on the basis of factors including treatment area and Fitzpatrick skin type.Conclusion: The 1550/1927‐nm dual laser system's ability to offer customizable settings positions it as a versatile tool in the growing field of esthetic medicine, particularly for addressing the multiple components of skin aging.
- Open Access
- 26 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 213-222
Brodalumab: Six-Year US Pharmacovigilance Report
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the USA, brodalumab has a boxed warning regarding suicidal ideation and behavior and is only available under a Risk Evaluation and Mitigation Strategy, but no causal association has been established. To assess long-term safety of brodalumab, we summarize pharmacovigilance data from 6 years of real-world clinical practice. Methods: Crude adverse event (AE) reporting rates per 100 patients were calculated for common AEs and AEs of special interest reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017 through August 14, 2023. Brodalumab exposure was estimated as time from the first to last prescription-dispensing authorization dates. Adverse events were defined by Medical Dictionary for Regulatory Activities v26.0 Preferred Terms and standardized MedDRA queries. Results: Data were collected from 5138 US patients (estimated exposure of 6900 patient-years). Over 6 years, 13 cases of adjudicated major adverse cardiovascular events were reported (0.25 events/100 patients). The rate of serious infections was 2.20 events/100 patients. Since the 5-year report, there was one new case of Candida infection and a serious fungal infection of the elbow. Among 57 reported malignancies affecting 49 patients, 4 were deemed possibly related to brodalumab. One new case of indeterminate inflammatory bowel disease unrelated to brodalumab was reported. No new suicide attempts were reported in year 6, and there were no completed suicides throughout 6 years. Conclusion: Pharmacovigilance data throughout 6 years are consistent with the safety profile of brodalumab established in clinical trials and previous US pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical
- 26 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 213-222
Open AccessBrodalumab: Six-Year US Pharmacovigilance Report
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the USA, brodalumab has a boxed warning regarding suicidal ideation and behavior and is only available under a Risk Evaluation and Mitigation Strategy, but no causal association has been established. To assess long-term safety of brodalumab, we summarize pharmacovigilance data from 6 years of real-world clinical practice. Methods: Crude adverse event (AE) reporting rates per 100 patients were calculated for common AEs and AEs of special interest reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017 through August 14, 2023. Brodalumab exposure was estimated as time from the first to last prescription-dispensing authorization dates. Adverse events were defined by Medical Dictionary for Regulatory Activities v26.0 Preferred Terms and standardized MedDRA queries. Results: Data were collected from 5138 US patients (estimated exposure of 6900 patient-years). Over 6 years, 13 cases of adjudicated major adverse cardiovascular events were reported (0.25 events/100 patients). The rate of serious infections was 2.20 events/100 patients. Since the 5-year report, there was one new case of Candida infection and a serious fungal infection of the elbow. Among 57 reported malignancies affecting 49 patients, 4 were deemed possibly related to brodalumab. One new case of indeterminate inflammatory bowel disease unrelated to brodalumab was reported. No new suicide attempts were reported in year 6, and there were no completed suicides throughout 6 years. Conclusion: Pharmacovigilance data throughout 6 years are consistent with the safety profile of brodalumab established in clinical trials and previous US pharmacovigilance reports, with no completed suicides and a low fungal infection rate. Graphical
- Open Access
- 12 September 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (10) , 2709-2726
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
Factors such as obesity, alcohol consumption, and tobacco use are associated with both increased psoriasis severity and inadequate response to systemic and biologic therapies. Obesity is linked to chronic inflammation, which can contribute to psoriasis pathogenesis. Fixed-dose therapies may have reduced efficacy in patients with a higher body mass index, while weight-based dosing can increase the burden of drug-specific side effects. Alcohol and nicotine from tobacco have also been shown to stimulate keratinocyte and immune cell proliferation and production of proinflammatory cytokines. While these risk factors are prevalent among patients with moderate-to-severe psoriasis, their influence on treatment outcomes may be overlooked when evaluating therapeutic options. Brodalumab is a fully human interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis. In this review, we describe the lifestyle-related risk factors associated with decreased response to treatment. We further summarize the post hoc analyses of brodalumab in participant subgroups with moderate-to-severe psoriasis and a history of prior biologic failure, obesity, and alcohol or tobacco use from two phase 3 clinical trials (AMAGINE-2 and AMAGINE-3; ClinicalTrials.gov identifiers: NCT01708603 and NCT01708629, respectively). Our review of clinical trial and real-world data suggests that brodalumab is an efficacious and safe treatment option for patients with lifestyle factors that increase the likelihood of treatment failure, allowing them to achieve skin clearance and improve quality of life.
- 12 September 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (10) , 2709-2726
Open AccessEfficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
Factors such as obesity, alcohol consumption, and tobacco use are associated with both increased psoriasis severity and inadequate response to systemic and biologic therapies. Obesity is linked to chronic inflammation, which can contribute to psoriasis pathogenesis. Fixed-dose therapies may have reduced efficacy in patients with a higher body mass index, while weight-based dosing can increase the burden of drug-specific side effects. Alcohol and nicotine from tobacco have also been shown to stimulate keratinocyte and immune cell proliferation and production of proinflammatory cytokines. While these risk factors are prevalent among patients with moderate-to-severe psoriasis, their influence on treatment outcomes may be overlooked when evaluating therapeutic options. Brodalumab is a fully human interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis. In this review, we describe the lifestyle-related risk factors associated with decreased response to treatment. We further summarize the post hoc analyses of brodalumab in participant subgroups with moderate-to-severe psoriasis and a history of prior biologic failure, obesity, and alcohol or tobacco use from two phase 3 clinical trials (AMAGINE-2 and AMAGINE-3; ClinicalTrials.gov identifiers: NCT01708603 and NCT01708629, respectively). Our review of clinical trial and real-world data suggests that brodalumab is an efficacious and safe treatment option for patients with lifestyle factors that increase the likelihood of treatment failure, allowing them to achieve skin clearance and improve quality of life.
- Open Access
- 9 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1349-1357
Brodalumab: 5-Year US Pharmacovigilance Report
Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Although the US prescribing information for brodalumab includes a boxed warning regarding suicidal ideation and behavior, no causal association has been demonstrated. Here, we summarize 5 years of pharmacovigilance data, from August 15, 2017, through August 14, 2022, reported to Ortho Dermatologics by US patients and healthcare providers. Methods Prevalence of the most common adverse events (AEs) listed in the brodalumab package insert (incidence ≥ 1%) and AEs of special interest are described. Brodalumab exposure was estimated as the time from the first to last prescription-dispensing authorization dates. Data were collected from 4744 patients in the USA, with an estimated exposure of 5815 patient-years. Results Over 5 years, 11 cases of adjudicated major adverse cardiovascular events were reported (0.23 events/100 patients), a rate lower than that experienced by patients in the international Psoriasis Longitudinal Assessment and Registry. There were 106 serious infections. No serious fungal infections were reported. There were 40 confirmed and 2 suspected COVID-19 cases, with no new COVID-19-related deaths. Of 49 reported malignancies among 42 patients, 3 were deemed possibly related to brodalumab. No completed suicides and no new suicidal attempts were reported. Conclusion Five-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and previous pharmacovigilance reports, with no new safety signals.
- 9 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1349-1357
Open AccessBrodalumab: 5-Year US Pharmacovigilance Report
Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Although the US prescribing information for brodalumab includes a boxed warning regarding suicidal ideation and behavior, no causal association has been demonstrated. Here, we summarize 5 years of pharmacovigilance data, from August 15, 2017, through August 14, 2022, reported to Ortho Dermatologics by US patients and healthcare providers. Methods Prevalence of the most common adverse events (AEs) listed in the brodalumab package insert (incidence ≥ 1%) and AEs of special interest are described. Brodalumab exposure was estimated as the time from the first to last prescription-dispensing authorization dates. Data were collected from 4744 patients in the USA, with an estimated exposure of 5815 patient-years. Results Over 5 years, 11 cases of adjudicated major adverse cardiovascular events were reported (0.23 events/100 patients), a rate lower than that experienced by patients in the international Psoriasis Longitudinal Assessment and Registry. There were 106 serious infections. No serious fungal infections were reported. There were 40 confirmed and 2 suspected COVID-19 cases, with no new COVID-19-related deaths. Of 49 reported malignancies among 42 patients, 3 were deemed possibly related to brodalumab. No completed suicides and no new suicidal attempts were reported. Conclusion Five-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and previous pharmacovigilance reports, with no new safety signals.